MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: A combined cross-sectional and longitudinal study

European Radiology

Volumn 19, Issue 8, 2009, Pages 2066-2074

  Bellmann Strobl, J ^a   Stiepani, H ^a   Wuerfel, J ^a,b   Bohner, G ^a   Paul, F ^a   Warmuth, C ^a   Aktas, O ^a   Wandinger, K P ^a   Zipp, F ^a   Klingebiel, Randolf ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Magnetisation transfer imaging; MR spectroscopy; Multiple sclerosis; White matter

Indexed keywords

BETA1A INTERFERON; CREATINE; GLATIRAMER; N ACETYLASPARTIC ACID;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SCORING SYSTEM; WHITE MATTER;

ADOLESCENT; ADULT; ARTERIOVENOUS FISTULA; BIOLOGICAL MARKERS; BRAIN; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NERVE FIBERS, MYELINATED; RECURRENCE; REMISSION, SPONTANEOUS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 67650826054     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-009-1364-z     Document Type: Article

References (44)

1. Pugliatti M, Sotgiu S, Rosati G (2002) The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104(3):182-191
2. Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58(6):840-846
3. Filippi M, Rovaris M (2000) Magnetisation transfer imaging in multiple sclerosis. J Neurovirol 6(Suppl 2):S115-S1120
4. Tedeschi G, Bonavita S, McFarland HF et al (2002) Proton MR spectroscopic imaging in multiple sclerosis. Neuroradiology 44(1):37-42
5. Inglese M, Rovaris M, Bianchi S et al (2001) Magnetic resonance imaging, magnetisation transfer imaging, and diffusion weighted imaging correlates of optic nerve, brain, and cervical cord damage in Leber's hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 70(4):444-449
6. Narayana PA (2005) Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J Neuroimaging 15(4 Suppl):46S-57S
7. Horsfield MA (2005) Magnetization transfer imaging in multiple sclerosis. J Neuroimaging 15(4 Suppl):58S-67S
8. Pascual-Lozano A, Martinez-Bisbal M, Bosca I et al (2006) Axonal damage and inflammation in early multiple sclerosis: Effects of subcutaneously interferon-beta-1a treatment. Mult Scler 12:S186
9. Narayanan S, De Stefano N, Francis GS et al (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248(11):979-986
10. Sarchielli P, Presciutti O, Tarducci R et al (1998) 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta-1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64(2):204-212
11. Parry A, Corkill R, Blamire AM et al (2003) Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 250(2):171-178
12. Richert ND, Ostuni JL, Bash CN et al (1998) Serial whole-brain magnetization transfer imaging in patients with relapsing-remitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 19(9):1705-1713
13. Kita M, Goodkin DE, Bacchetti P et al (2000) Magnetization transfer ratio in new MS lesions before and during therapy with IFNbeta-1a. Neurology 54(9):1741-1745
14. McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121-127
15. Cutter GR, Baier ML, Rudick RA et al (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122:871-882
16. Rovaris M, Filippi M, Minicucci L et al (2000) Cortical/subcortical disease burden and cognitive impairment in patients with multiple sclerosis. AJNR Am J Neuroradiol 21(2):402-408
17. Bakshi R, Thompson AJ, Rocca MA et al (2008) MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 7(7):615-625
18. Zivadinov R, Stosic M, Cox J et al (2008) The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome. J Neurol 255(0):61-74
19. Chen JT, Collins DL, Atkins HL et al (2008) Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 63(2):254-262
20. Simmons ML, Frondoza CG, Coyle JT (1991) Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 45(1):37-45
21. Zivadinov R (2007) Can imaging techniques measure neuroprotection and remyelination in multiple sclerosis? Neurology 68(22 Suppl 3):S72-S82
22. Giacomini PS, Arnold DL (2008) Non-conventional MRI techniques for measuring neuroprotection, repair and plasticity in multiple sclerosis. Curr Opin Neurol 21(3):272-277
23. Rovira A, Leon A (2008) MR in the diagnosis and monitoring of multiple sclerosis: An overview. Eur J Radiol 67(3):409-414
24. Inglese M (2006) Multiple sclerosis: New insights and trends. AJNR Am J Neuroradiol 27(5):954-957
25. Khaleeli Z, Sastre-Garriga J, Ciccarelli O et al (2007) Magnetisation transfer ratio in the normal appearing white matter predicts progression of disability over 1 year in early primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 78(10):1076-1082
26. Wattjes MP, Harzheim M, Lutterbey GG et al (2008) Prognostic value of high-field proton magnetic resonance spectroscopy in patients presenting with clinically isolated syndromes suggestive of multiple sclerosis. Neuroradiology 50(2):123-129
27. De Stefano N, Guidi L, Stromillo ML et al (2003) Imaging neuronal and axonal degeneration in multiple sclerosis. Neurol Sci 24(Suppl 5):S283-S286
28. Filippi M, Rocca MA, Comi G (2003) The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis. Lancet Neurol 2(6):337-346
29. Pascual AM, Martinez-Bisbal MC, Bosca I et al (2007) Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology 69(1):63-67
30. Inglese M, Li BS, Rusinek H et al (2003) Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis. Magn Reson Med 50(1):190-195
31. Wattjes MP, Harzheim M, Lutterbey GG et al (2008) High field MR imaging and (1)H-MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis: Correlation between metabolic alterations and diagnostic MR imaging criteria. J Neurol 255(1):56-63
32. Rieckmann P (2005) Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Int MS J 12(2):42-51
33. Neema M, Stankiewicz J, Arora A et al (2007) MRI in multiple sclerosis: what's inside the toolbox? Neurotherapeutics 4(4):602-617
34. Adalsteinsson E, Langer-Gould A, Homer RJ et al (2003) Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 24(10):1941-1945
35. Jacobs LD, Cookfair DL, Rudick RA et al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39(3):285-294
36. PRISMS Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet Neurol 352(9139):1498-1504
37. Kappos L, Freedman MS, Polman CH et al (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: A 3-year follow-up analysis of the BENEFIT study. Lancet 370(9585):389-397
38. Chen JT, Kuhlmann T, Jansen GH et al (2007) Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion. Neuroimage 36(4):1152-1158
39. Deloire MS, Salort E, Bonnet M et al (2005) Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76(4):519-526
40. Vrenken H, Pouwels PJ, Ropele S et al (2007) Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. Mult Scler 13(6):708-716
41. Laule C, Vavasour IM, Whittall KP et al (2003) Evolution of focal and diffuse magnetisation transfer abnormalities in multiple sclerosis. J Neurol 250(8):924-931
42. Horakova D, Cox JL, Havrdova E et al (2008) Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry 79(4):407-414
43. Davies GR, Ramio-Torrenta L, Hadjiprocopis A (2004) Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 75(7):998-1002
44. Oreja-Guevara C, Charil A, Caputo D et al (2006) Magnetization transfer magnetic resonance imaging and clinical changes in patients with relapsing-remitting multiple sclerosis. Arch Neurol 63(5):736-440